BDS (Gold Medalist), Certified Lactation Consultant – BPNI Delhi, Maternal & Infant Nutrition Expert · 15 years experience


Tay-Sachs disease is a rare, inherited (genetic) disorder in which a missing enzyme called hexosaminidase A (HEXA) causes a fatty substance (GM2 ganglioside) to build up in the nerve cells of the brain and spinal cord, progressively destroying them (MedlinePlus / NIH) (Cleveland Clinic). It is caused by mutations in the HEXA gene on chromosome 15 and is inherited in an autosomal recessive pattern, meaning a child must inherit a faulty gene from both parents (NCBI / GeneReviews). The most common form, infantile Tay-Sachs, appears around 3 to 6 months of age and is sadly fatal by early childhood. There is currently no cure; care is supportive. Prevention is possible through genetic counselling, carrier screening and IVF with preimplantation genetic testing.
Quick Answer
Tay-Sachs disease is a fatal inherited disorder where a missing HEXA enzyme lets a fatty substance destroy brain and nerve cells. It is autosomal recessive, so a child must inherit the faulty gene from both parents. The infantile form appears by 6 months. There is no cure; treatment is supportive, and carrier screening enables prevention.
Author: Ishmeet Kaur, Senior Health Content Editor, Mylo Parenting Desk Medically reviewed by: Mylo Editorial Board, aligned with ACOG carrier screening guidance, NIH / MedlinePlus Genetics and FOGSI genetic counselling recommendations Last updated: 11 June 2026
Medical Disclaimer: This article is for informational purposes only and not a substitute for professional medical or genetic advice. If you have a family history of Tay-Sachs disease, belong to a higher-risk group, or are planning a pregnancy, please consult a genetic counsellor or your doctor for carrier screening and personalised guidance.
Tay-Sachs is a rare, inherited, fatal nerve-destroying disorder (MedlinePlus)
Caused by a missing HEXA enzyme leading to toxic ganglioside buildup in nerve cells
Inherited in an autosomal recessive pattern (both parents must be carriers) (NCBI GeneReviews)
If both parents are carriers, each pregnancy has a 25% chance of an affected child
Four forms: infantile (most common and severe), juvenile, chronic and late-onset (adult)
A classic sign is a "cherry-red spot" in the eye seen on examination
No cure exists; treatment is supportive and focused on comfort
Carrier screening before pregnancy is the most effective prevention (ACOG)
Tay-Sachs disease is a rare genetic disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord (Cleveland Clinic).
It happens because the body is missing or low on an enzyme called hexosaminidase A (HEXA). This enzyme normally breaks down a fatty substance called GM2 ganglioside. Without enough HEXA:
GM2 ganglioside builds up to toxic levels in nerve cells
This buildup damages and kills neurons over time
The result is progressive loss of physical and mental function
Tay-Sachs belongs to a group of conditions called lysosomal storage disorders (MedlinePlus).
Tay-Sachs is caused by mutations (changes) in the HEXA gene, located on chromosome 15 (NCBI GeneReviews).
The HEXA gene gives instructions to make the hexosaminidase A enzyme
When this gene is faulty, the enzyme is missing or does not work
Without the enzyme, fatty gangliosides accumulate and poison nerve cells
Tay-Sachs follows an autosomal recessive inheritance pattern (MedlinePlus):
Every person has two copies of the HEXA gene (one from each parent)
A carrier has one faulty copy and one normal copy and is healthy
A child develops Tay-Sachs only if they inherit a faulty copy from BOTH parents
Outcome | Chance |
|---|---|
Child has Tay-Sachs (two faulty genes) | 25% |
Child is a healthy carrier (one faulty gene) | 50% |
Child is completely unaffected (two normal genes) | 25% |
These odds apply to every pregnancy independently, not across multiple pregnancies. Two carriers can have an affected child even if previous children were healthy (NCBI GeneReviews).
There are four forms, defined by the age symptoms begin (Cleveland Clinic) (MedlinePlus):
Symptoms appear around 3 to 6 months of age:
Exaggerated startle response to sounds
"Cherry-red spot" in the eye (seen by doctor)
Loss of previously gained skills (rolling, sitting)
Muscle weakness and floppiness
Progressive loss of vision and hearing
Seizures
Difficulty swallowing
Paralysis over time
Sadly, this form is fatal, usually by 3 to 5 years of age (NCBI GeneReviews).
Symptoms appear between ages 2 and 10:
Slower progression than infantile form
Problems with coordination and speech
Muscle weakness
Cognitive decline
Usually fatal in adolescence
A rarer form with slower, milder progression:
Muscle weakness
Speech and coordination difficulties
Symptoms begin in childhood but progress slowly
Appears after age 20 to 30:
Muscle weakness and cramping
Unsteady walking (ataxia)
Slurred speech
Tremors
Memory and psychiatric changes
Does not usually shorten lifespan but affects quality of life
Type | Onset Age | Severity | Life Expectancy |
|---|---|---|---|
Infantile | 3 to 6 months | Most severe | 3 to 5 years |
Juvenile | 2 to 10 years | Severe | Adolescence |
Chronic | Childhood | Moderate, slow | Variable |
Late-onset (adult) | 20 to 30 years | Mild to moderate | Usually normal |
Anyone can be a carrier, but the risk is higher in certain populations with a founder genetic effect (MedlinePlus) (ACOG):
Group | Carrier Risk |
|---|---|
Ashkenazi (Eastern European) Jewish | About 1 in 27 |
French Canadian (certain communities) | Elevated |
Cajun (Louisiana, USA) | Elevated |
Old Order Amish (certain communities) | Elevated |
General population | About 1 in 250 to 300 |
While Tay-Sachs is rare in the general Indian population, carrier screening is still valuable for couples with a family history, consanguineous (related-by-blood) marriages, or unexplained previous infant deaths. Consanguineous marriage increases the chance both partners carry the same rare recessive gene (FOGSI).
Diagnosis combines clinical, enzyme and genetic testing (Cleveland Clinic) (NCBI GeneReviews):
Measures the level of hexosaminidase A in blood
Low or absent enzyme confirms Tay-Sachs
Also used to identify carriers (intermediate levels)
Identifies specific HEXA gene mutations
Confirms diagnosis and carrier status
A doctor may see the characteristic cherry-red spot on the retina (macula)
If both parents are known carriers (ACOG):
Chorionic villus sampling (CVS) at 10 to 13 weeks
Amniocentesis at 15 to 20 weeks
Done during IVF, embryos are tested before implantation
Allows selection of unaffected embryos
Currently, there is no cure for Tay-Sachs disease (MedlinePlus). Treatment is supportive (palliative) and focuses on comfort and quality of life:
Anti-seizure medications to control seizures
Respiratory care (chest physiotherapy, suctioning, infection management)
Feeding support (special feeding techniques or feeding tubes for swallowing difficulty)
Pain and comfort management
Physical therapy to maintain joint flexibility
Nutritional support
Emotional and psychological support for the family
Scientists are exploring (NCBI GeneReviews):
Enzyme replacement therapy
Gene therapy (to deliver a working HEXA gene)
Substrate reduction therapy
Stem cell and bone marrow approaches
These remain experimental and are not yet standard treatments.
Because there is no cure, prevention through screening and counselling is the most powerful tool (ACOG):
A simple blood test checks if you carry the HEXA mutation
Recommended especially for higher-risk groups and couples with family history
Ideally done before conceiving (preconception)
A genetic counsellor explains your risk and options
Especially important for consanguineous couples or those with a family history
If both partners are carriers, options include (NCBI GeneReviews):
IVF with preimplantation genetic testing (PGT) to select unaffected embryos
Prenatal diagnosis (CVS or amniocentesis) during natural pregnancy
Use of donor egg or sperm (from a non-carrier)
Adoption
Consanguineous marriage: In communities where marriage between blood relatives is common, the risk of recessive disorders like Tay-Sachs rises. Carrier screening is strongly advised (FOGSI)
Unexplained infant loss: If a family has experienced unexplained infant deaths or progressive neurological decline in a baby, genetic evaluation is important
Preconception counselling: Increasingly available at Indian fertility centres and genetic clinics in metros
Cost of testing: Carrier screening panels in India typically range from INR 5,000 to INR 25,000 depending on the number of conditions tested
Availability: Major hospitals (AIIMS, CMC Vellore, Sankara Nethralaya and private genetic labs) offer enzyme assays, DNA testing and genetic counselling
Stigma reduction: Genetic conditions are not anyone's "fault"; carrier status is common and screening is a responsible, private health step
Insurance: Genetic testing is not always covered; check your policy and ask the clinic about package costs
Myth | Fact | Source |
|---|---|---|
"Tay-Sachs only affects Jewish families" | False. It occurs in all populations; risk is just higher in some groups | |
"If one child is healthy, the next will be too" | False. Each pregnancy has an independent 25% risk if both parents are carriers | |
"Carriers have symptoms" | False. Carriers are healthy and usually have no symptoms | |
"There is a cure if caught early" | False. There is currently no cure; care is supportive | |
"Tay-Sachs can be caught from someone" | False. It is genetic and inherited, not contagious | |
"Screening is only for women" | False. Both partners should be screened; it takes two carriers | |
"Healthy parents cannot have an affected child" | False. Healthy carrier parents can have an affected child |
Tay-Sachs is caused by mutations in the HEXA gene on chromosome 15, which lead to a deficiency of the enzyme hexosaminidase A. Without this enzyme, a fatty substance (GM2 ganglioside) builds up and destroys nerve cells in the brain and spinal cord (MedlinePlus).
Tay-Sachs ek rare genetic (vanshanugat) bimari hai jismein HEXA naam ka enzyme missing hota hai. Iske bina ek fatty substance brain aur nerve cells mein jama ho kar unhe nuksaan pahunchata hai. Ye dono parents se faulty gene milne par hi hoti hai (autosomal recessive). Sabse common infantile form 6 mahine ki umar tak dikhti hai. Iska abhi koi ilaaj nahi hai, lekin carrier screening se isse roka ja sakta hai.
No. There is currently no cure for Tay-Sachs disease. Treatment is supportive, focusing on managing symptoms like seizures, breathing difficulties and feeding problems, and on maximising comfort and quality of life (MedlinePlus). Gene and enzyme therapies are being researched but are not yet available as standard treatment.
It is inherited in an autosomal recessive pattern. A child must inherit a faulty HEXA gene from both parents to develop the disease. If both parents are carriers, each pregnancy has a 25% chance the child is affected, a 50% chance the child is a healthy carrier, and a 25% chance the child is completely unaffected (NCBI GeneReviews).
Children with the infantile form sadly usually live only to 3 to 5 years of age due to progressive nerve cell destruction (Cleveland Clinic). The late-onset adult form usually does not shorten lifespan.
Yes. If both parents are carriers, each pregnancy still has a 75% chance the baby will NOT have Tay-Sachs (50% healthy carrier plus 25% completely unaffected). With IVF and preimplantation genetic testing (PGT), carrier couples can select unaffected embryos and have a healthy baby (ACOG).
Carrier screening is recommended for (ACOG):
People with Ashkenazi Jewish, French Canadian or Cajun ancestry
Couples with a family history of Tay-Sachs
Consanguineous (blood-related) couples
Anyone planning pregnancy who wants to know their carrier status
Sabse best time hai pregnancy se pehle (preconception). Ek simple blood test (enzyme assay ya DNA test) se pata chal jata hai ki aap carrier hain ya nahi. Agar family history hai, blood relation mein shaadi hai, ya pehle koi unexplained infant loss hua hai, toh dono partners ko screening karwani chahiye. Genetic counsellor se baat karein.
The cherry-red spot in the eye is a classic and common finding in infantile Tay-Sachs, seen on retinal examination (Cleveland Clinic). It may be less prominent or absent in late-onset forms. Diagnosis is confirmed with enzyme and genetic testing, not the eye sign alone.
Tay-Sachs is rare in the general Indian population compared to high-risk groups like Ashkenazi Jews. However, it can still occur, especially in consanguineous marriages where both partners may carry the same rare recessive gene. Carrier screening is advisable for at-risk couples (FOGSI).
A carrier has one faulty HEXA gene and one normal gene; they are healthy with no symptoms but can pass the faulty gene to children. An affected person has two faulty genes (one from each parent) and develops the disease (MedlinePlus).
Yes. If both parents are known carriers, prenatal tests can detect Tay-Sachs in the baby: chorionic villus sampling (CVS) at 10 to 13 weeks or amniocentesis at 15 to 20 weeks (ACOG). These should be discussed with a genetic counsellor.
MedlinePlus / National Institutes of Health (NIH). "Tay-Sachs Disease." https://medlineplus.gov/genetics/condition/tay-sachs-disease/
Cleveland Clinic. "Tay-Sachs Disease." https://my.clevelandclinic.org/health/diseases/tay-sachs-disease
NCBI / GeneReviews. "Hexosaminidase A Deficiency (Tay-Sachs Disease)." https://www.ncbi.nlm.nih.gov/books/NBK1218/
American College of Obstetricians and Gynecologists (ACOG). "Carrier Screening for Genetic Conditions." https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions
National Tay-Sachs and Allied Diseases Association (NTSAD). https://www.ntsad.org/
FOGSI (Federation of Obstetric and Gynaecological Societies of India). https://www.fogsi.org/
National Human Genome Research Institute (NIH). "About Tay-Sachs Disease." https://www.genome.gov/Genetic-Disorders/Tay-Sachs-Disease
Gentle support for your fertility and preconception health, helping you prepare your body for a healthy pregnancy ahead.




This content is for informational purposes only and should not replace professional medical advice. Consult with a physician or other health care professional if you have any concerns or questions about your health. If you rely on the information provided here, you do so solely at your own risk.

Mylo wins Forbes D2C Disruptor award

Mylo wins The Economic Times Promising Brands 2022
Baby Carrier | Baby Soap | Stretch Marks Cream | Baby Cream | Baby Shampoo | Baby Massage Oil | Baby Hair Oil | Stretch Marks Oil | Baby Body Wash | Baby Powder | Baby Lotion | Diaper Rash Cream | Teether | Baby Kajal |